Hospital
Fulton County Health Center
Fulton County Health Center was paid $5.97M by Medicaid between Jan 2018 and Dec 2024, across 128 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoFULTON COUNTY HEALTH CENTER
WAUSEON, OH 43567
WAUSEON, OH 43567
33aNPI1548279714assigned 08/05/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$5.97M
24GClaims128,964
24DCodes billed128
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Ohio
Rank by total paid#6 of 6
Median peer was paid$22.82M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,524 | $317K | |
| 2019 | 7,409 | $321K | |
| 2020 | 5,942 | $361K | |
| 2021 | 9,040 | $503K | |
| 2022 | 9,745 | $550K | |
| 2023 | 53,548 | $2.13M | |
| 2024incomplete | 35,756 | $1.79M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 14,211 | 12,900 | $1.61M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 7,808 | 6,796 | $899K |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 2,530 | 1,590 | $705K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.3% | 4,310 | 947 | $314K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.1% | 878 | 705 | $248K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 1,714 | 1,397 | $217K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 786 | 636 | $169K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 1,189 | 1,040 | $162K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 1,377 | 740 | $151K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 1,138 | 975 | $132K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 364 | 278 | $106K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 483 | 352 | $100K |
116 more codes
| 80053 | Comprehensive metabolic panel | 1.3% | 8,166 | $77K |
| G0378 | Hospital observation service, per hour | 1.2% | 1,006 | $72K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 1,003 | $66K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.0% | 431 | $62K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 426 | $58K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 596 | $51K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,157 | $46K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,411 | $43K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 304 | $38K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 164 | $36K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,755 | $34K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 381 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,527 | $32K |
| 97161 | <1% | 565 | $30K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 972 | $29K |
| 87070 | <1% | 1,315 | $29K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 662 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,790 | $22K |
| 81513 | <1% | 177 | $21K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 631 | $19K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,097 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,459 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 627 | $16K |
| 82728 | <1% | 710 | $14K | |
| 80061 | Lipid panel | <1% | 1,025 | $14K |
| 73630 | <1% | 443 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,841 | $13K |
| 73610 | <1% | 337 | $12K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 108 | $11K |
| 95811 | <1% | 16 | $10K | |
| 73562 | <1% | 232 | $9K | |
| 84439 | <1% | 701 | $9K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 314 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 608 | $7K |
| 80306 | <1% | 773 | $7K | |
| 81001 | <1% | 5,714 | $7K | |
| 82607 | <1% | 377 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 118 | $6K |
| 84702 | <1% | 304 | $6K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,828 | $6K |
| 86140 | <1% | 569 | $6K | |
| 87186 | <1% | 1,168 | $6K | |
| 83540 | <1% | 475 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 959 | $5K |
| 84484 | <1% | 3,021 | $5K | |
| 85027 | <1% | 1,234 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,484 | $5K |
| 73030 | <1% | 139 | $5K | |
| 73560 | <1% | 92 | $5K | |
| 87481 | <1% | 179 | $4K | |
| 83735 | <1% | 901 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 196 | $4K |
| 83550 | <1% | 423 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,573 | $4K |
| 80320 | <1% | 249 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,828 | $3K |
| 82553 | <1% | 426 | $3K | |
| 73130 | <1% | 133 | $3K | |
| 82746 | <1% | 206 | $3K | |
| 86308 | <1% | 112 | $3K | |
| 72100 | <1% | 63 | $3K | |
| 74018 | <1% | 92 | $3K | |
| 85610 | <1% | 1,121 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 15 | $3K |
| 95816 | <1% | 17 | $2K | |
| 83880 | <1% | 496 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 221 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 96 | $2K |
| 73502 | <1% | 45 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 658 | $2K |
| 85652 | <1% | 403 | $2K | |
| 83690 | <1% | 2,048 | $2K | |
| 82805 | <1% | 50 | $1K | |
| 84703 | <1% | 1,552 | $1K | |
| 80076 | <1% | 194 | $1K | |
| 82962 | <1% | 722 | $1K | |
| 96367 | <1% | 22 | $957.76 | |
| 87040 | <1% | 377 | $942.96 | |
| 83605 | <1% | 769 | $904.18 | |
| 73110 | <1% | 45 | $902.68 | |
| 85730 | <1% | 667 | $881.02 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 37 | $870.39 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 16 | $561.34 |
| 87341 | <1% | 33 | $545.02 | |
| 87205 | <1% | 91 | $542.43 | |
| 97116 | <1% | 32 | $540.28 | |
| 82043 | <1% | 63 | $486.90 | |
| 87522 | Neg quan hep c or qual rna | <1% | 18 | $461.21 |
| 85379 | <1% | 424 | $455.78 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13 | $447.28 |
| 73080 | <1% | 15 | $414.29 | |
| 86593 | <1% | 14 | $370.96 | |
| 82550 | <1% | 445 | $330.23 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 16 | $315.77 |
| 36415 | Collection of venous blood by venipuncture | <1% | 468 | $308.06 |
| 86703 | <1% | 14 | $302.64 | |
| 83655 | <1% | 12 | $285.65 | |
| 96376 | <1% | 463 | $224.46 | |
| 86900 | <1% | 21 | $222.03 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 81 | $210.61 |
| 85018 | <1% | 27 | $133.55 | |
| 85014 | <1% | 15 | $115.89 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 492 | $101.79 |
| 84100 | <1% | 21 | $87.32 | |
| 81025 | <1% | 100 | $57.60 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 341 | $50.14 |
| A9270 | Non-covered item or service | <1% | 1,538 | $43.82 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 185 | $20.08 |
| 86901 | <1% | 21 | $14.11 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 155 | $13.19 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 95 | $12.68 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 646 | $11.49 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 94 | $8.60 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 30 | $6.06 |
| 80329 | 0% | 13 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFINN, PATRICIA (CEO)
| Provider | Location | Paid |
|---|---|---|
| FCHC Medical Care, LLC | Wauseon, OH | $1.68M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.